Form 4: Heron Therapeutics, Inc. /De/ COO Reports Stock Transaction
Insider Transaction (Form 4)
Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on August 6, 2026.
Summary
- Option exercise/conversion: acquired 31,250 Common Stock on August 6, 2026; holds 179,789 after (Direct).
- Tax/exercise-price withholding: disposed of 8,888 Common Stock at $0.50 ($4,444) on August 6, 2026; holds 170,901 after (Direct).
- Option exercise/conversion: disposed of 31,250 Restricted Stock Units on August 6, 2026; holds 343,750 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mark Earl Hensley — Officer (Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-06 | Option exercise/conversion | Common Stock | 31,250 | — | — | 179,789 |
| 2026-08-06 | Tax/exercise-price withholding | Common Stock | 8,888 | $1 | $4.4K | 170,901 |
| 2026-08-06 | Option exercise/conversion | Restricted Stock Units | 31,250 | — | — | 343,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-06 | Option exercise/conversion (31,250 shares) |
| 2026-08-06 | Tax/exercise-price withholding (8,888 shares) |
| 2026-08-06 | Option exercise/conversion (31,250 shares) |
Keywords
insider transaction, Form 4, HRTX, HERON THERAPEUTICS, INC. /DE/, neutral, Mark Earl Hensley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.